GO:0006207 'de novo' pyrimidine nucleobase biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006207 describes the chemical reactions and pathways that build pyrimidine nucleobases from simple precursors, starting with ring formation.
• The pathway is essential for nucleotide supply, and its disruption affects DNA/RNA synthesis, cell proliferation, and virulence in pathogens.
• In plants, de novo pyrimidine synthesis occurs mainly outside plastids, while salvage pathways rely on nucleobase importers.
• Cancer cells often rewire pyrimidine biosynthesis to support rapid proliferation and DNA repair.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of each enzymatic step.
• The pathway is a validated target for antimicrobial, antiparasitic, and anticancer drug discovery.
Description
The Gene Ontology term GO:0006207, 'de novo' pyrimidine nucleobase biosynthetic process, defines the set of chemical reactions that synthesize pyrimidine nucleobases from simpler precursors, beginning with the formation of the pyrimidine ring. Pyrimidine nucleobases are fundamental building blocks of nucleotides, nucleic acids, and many cofactors, and their de novo synthesis is a core metabolic route in organisms ranging from bacteria to humans. Understanding this process is critical because it connects central carbon and nitrogen metabolism to genome replication, repair, and gene expression. In pathogens such as Toxoplasma gondii, de novo pyrimidine biosynthesis is required for virulence, making the pathway an attractive drug target. In plants, the pathway is compartmentalized and integrated with salvage mechanisms, highlighting evolutionary diversity in nucleobase production. Researchers study GO:0006207 to uncover how cells balance nucleotide supply with demand, how metabolic flux is regulated, and how perturbations contribute to disease.
'de novo' pyrimidine nucleobase biosynthetic process At A Glance
| GO ID | GO:0006207 |
|---|---|
| GO term | 'de novo' pyrimidine nucleobase biosynthetic process |
| Ontology | biological_process |
| Synonym | 'de novo' pyrimidine base anabolism; 'de novo' pyrimidine base biosynthesis; 'de novo' pyrimidine base biosynthetic process; 'de novo' pyrimidine base formation; 'de novo' pyrimidine base synthesis |
| Major function | Synthesis of pyrimidine nucleobases from simple precursors, initiating with pyrimidine ring formation |
| Related pathways | Pyrimidine nucleotide biosynthesis, salvage pathways, and nucleotide homeostasis |
| Organismal relevance | Required for virulence in Toxoplasma gondii and for plant development |
| Disease links | Cancer metabolic reprogramming and DNA repair defects |
What Is GO:0006207?
GO:0006207 describes the chemical reactions and pathways that result in the formation of pyrimidine nucleobases, which are 1,3-diazine organic nitrogenous bases, starting from simpler precursors and involving the de novo synthesis of the pyrimidine ring. This process is distinct from salvage pathways that recycle preformed nucleobases.
Why Is 'de novo' pyrimidine nucleobase biosynthetic process Important in Cell Biology?
GO:0006207 is central to nucleotide metabolism because it provides the pyrimidine nucleobases needed for DNA and RNA synthesis, as well as for coenzymes and signaling molecules. Its activity must be tightly coordinated with salvage pathways to meet cellular demand, and imbalances can lead to genome instability, impaired proliferation, or pathogen persistence. In cancer, upregulation of de novo pyrimidine biosynthesis supports rapid growth and resistance to DNA-damaging agents. In infectious disease, the pathway is essential for the virulence of parasites like Toxoplasma gondii, and bacteria rely on nucleotide availability for adaptation and virulence. In plants, de novo synthesis and salvage are spatially separated, which is critical for development and stress responses. Thus, understanding this process offers insights into fundamental biology and multiple disease contexts.
• Provides pyrimidine nucleobases for DNA and RNA synthesis, supporting cell proliferation.
• Required for virulence of Toxoplasma gondii, making it a drug target.
• Influences bacterial adaptation and virulence through nucleotide availability.
• Linked to cancer cell metabolic reprogramming and DNA repair capacity.
• Essential for plant development and stress responses, with compartmentalized synthesis.
• Interacts with salvage pathways to maintain nucleotide homeostasis.
• Target for antimicrobial and antiparasitic therapies.
• Provides biomarkers for metabolic disorders and cancer diagnostics.
• Enables studies of metabolic flux and enzyme evolution.
• Supports synthetic biology efforts to engineer nucleotide production.
What Happens During 'de novo' pyrimidine nucleobase biosynthetic process?
Initiation and Pyrimidine Ring Formation
In simple terms: The cell starts building a pyrimidine ring from simple molecules like ammonia and bicarbonate.
The de novo pathway begins with the assembly of the pyrimidine ring from simpler precursors, a process that can occur through both enzymatic and nonenzymatic routes. In this initial stage, small molecules such as carbamoyl phosphate and aspartate are used to form the ring structure, which is the hallmark of pyrimidine nucleobase biosynthesis. This step is critical because it commits the cell to de novo synthesis rather than salvage.
Formation of Orotate and UMP
In simple terms: The ring is further modified to make orotate, which is then converted to UMP, a key nucleotide.
Following ring formation, the pathway proceeds through intermediates such as dihydroorotate and orotate, ultimately producing uridine monophosphate (UMP). In plants, these reactions occur mainly outside plastids, and the resulting UMP serves as a precursor for all other pyrimidine nucleotides. The enzyme steps involved are conserved across many organisms, though compartmentation differs.
Nucleobase Interconversion and Salvage Interplay
In simple terms: The newly made nucleobases can be recycled or further modified to meet cellular needs.
De novo synthesized pyrimidine nucleobases can enter salvage pathways or be converted into other nucleotides. In Arabidopsis, a previously undiscovered nucleobase importer provides substrates for the essential salvage pathway, showing that de novo synthesis and salvage are tightly integrated. This interplay ensures nucleotide availability under varying conditions.
Regulation by Nucleotide Demand
In simple terms: The pathway speeds up or slows down based on how much nucleotide the cell needs.
The de novo pyrimidine biosynthetic process is regulated in response to cellular demand for nucleotides, which can be driven by proliferation, DNA damage, or stress. In bacteria, nucleotide availability acts as a driver of adaptation and virulence, influencing pathway expression. In cancer, upregulation of this pathway supports DNA repair and bypass of lesions.
Nonenzymatic and Alternative Routes
In simple terms: Some steps can happen without enzymes, providing clues about early life chemistry.
A nonenzymatic analog of pyrimidine nucleobase biosynthesis has been demonstrated, suggesting that primitive routes may have existed before enzymes evolved. This finding broadens our understanding of how pyrimidine nucleobases could form under prebiotic conditions and informs synthetic biology approaches.
Key Genes Involved in GO:0006207 'de novo' pyrimidine nucleobase biosynthetic process
The following genes and proteins are central to the de novo pyrimidine nucleobase biosynthetic process, based on experimental evidence from model organisms and human cells.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CAD | Multienzyme complex catalyzing first steps of pyrimidine biosynthesis | Target for cancer metabolism studies |
| DHODH | Catalyzes dihydroorotate to orotate, a key step in de novo synthesis | Inhibitor target in cancer and autoimmune diseases |
| UMPS | Converts orotate to UMP, linking to nucleotide pools | Mutations cause orotic aciduria; model for metabolic disorders |
| CTPS1 | Synthesizes CTP from UTP, a downstream pyrimidine nucleotide | Required for lymphocyte proliferation; cancer target |
| NUDT5 | Regulates nucleotide synthesis and uridine sensitivity | Identified as regulator of nucleotide synthesis |
| COQ2 | Involved in coenzyme Q biosynthesis; demethoxy-coenzyme Q links to nucleotide synthesis | Regulator of nucleotide synthesis |
| TgCAD | Toxoplasma gondii CAD homolog essential for virulence | Drug target for toxoplasmosis |
| TgDHODH | Toxoplasma dihydroorotate dehydrogenase | Validated antiparasitic target |
| PYR1 | Plant pyrimidine biosynthesis gene | Studied for compartmentation and salvage |
| PYR2 | Plant pyrimidine biosynthesis gene | Studied for compartmentation and salvage |
| PYR3 | Plant pyrimidine biosynthesis gene | Studied for compartmentation and salvage |
| PYR4 | Plant pyrimidine biosynthesis gene | Studied for compartmentation and salvage |
| PYR5 | Plant pyrimidine biosynthesis gene | Studied for compartmentation and salvage |
| PYR6 | Plant pyrimidine biosynthesis gene | Studied for compartmentation and salvage |
| NUP1 | Nucleobase importer in Arabidopsis | Provides substrates for salvage pathway |
| PyrB | Bacterial aspartate transcarbamoylase | Model for allosteric regulation |
| PyrC | Bacterial dihydroorotase | Model for enzyme mechanism |
| PyrD | Bacterial dihydroorotate dehydrogenase | Target for antibacterial drugs |
How Is 'de novo' pyrimidine nucleobase biosynthetic process Regulated?
The de novo pyrimidine nucleobase biosynthetic process is regulated at multiple levels in response to cellular demand for nucleotides. In cancer, upregulation of this pathway supports DNA repair and bypass of DNA lesions, and its activity can be influenced by oncogenic signaling. In bacteria, nucleotide availability drives adaptation and virulence, with pathway expression responding to environmental cues. In plants, the pathway is compartmentalized and coordinated with salvage, and a nucleobase importer regulates substrate supply. Additionally, uridine-sensitized screening has identified NUDT5 and demethoxy-coenzyme Q as regulators of nucleotide synthesis, linking mitochondrial function to pyrimidine production.
'de novo' pyrimidine nucleobase biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CAD | Cancer proliferation and drug resistance | Knockout and overexpression in cancer cell lines |
| DHODH | Cancer and autoimmune disorders | Point mutation to study inhibitor resistance |
| UMPS | Orotic aciduria | Knock-in of patient mutations in cell lines |
| TgCAD | Toxoplasma virulence | Knockout in T. gondii |
| NUDT5 | Nucleotide synthesis regulation | Knockout and rescue in human cells |
Cancer Metabolism and DNA Repair
Cancer cells frequently upregulate de novo pyrimidine biosynthesis to sustain rapid proliferation and to support DNA repair and lesion bypass. This metabolic rewiring can confer resistance to chemotherapy and radiation, making the pathway a target for therapeutic intervention. Inhibitors of key enzymes such as DHODH and CTPS1 are under investigation.
Infectious Diseases: Toxoplasma and Bacteria
De novo pyrimidine biosynthesis is required for the virulence of Toxoplasma gondii, and genetic disruption of the pathway attenuates infection in animal models. In bacteria, nucleotide availability drives adaptation and virulence, and the pathway is considered a target for new antibiotics.
Inherited Metabolic Disorders
Defects in pyrimidine biosynthesis enzymes, such as UMPS, cause orotic aciduria, a rare inherited disorder characterized by anemia and developmental delay. Studying these mutations provides insight into pathway flux and nucleotide homeostasis.
Plant Development and Stress
In plants, de novo pyrimidine synthesis occurs mainly outside plastids, and a nucleobase importer supports the essential salvage pathway. Disruption of these processes affects growth and stress responses, with implications for crop improvement.
From 'de novo' pyrimidine nucleobase biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the gene essential for de novo pyrimidine synthesis? | CRISPR knockout cell line |
| Does a specific mutation alter enzyme activity? | Point mutation knock-in |
| Can a tagged protein track pathway localization? | Tagged knock-in |
| Does overexpression drive proliferation? | Overexpression cell line |
| Which regulators control pathway flux? | CRISPR library screening |
| How does pathway disruption affect virulence? | Pathogen knockout model |
How to Study the 'de novo' pyrimidine nucleobase biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Metabolic flux analysis | Flux through de novo pathway | Cancer metabolism studies |
| CRISPR screening | Gene essentiality and regulators | Identify nucleotide synthesis regulators |
| Enzyme activity assay | Catalytic activity of pathway enzymes | Inhibitor testing and mutation characterization |
| RNA-seq | Expression of pathway genes | Response to stress or drugs |
| Proteomics | Protein abundance and modifications | Pathway regulation |
| Isotope tracing | Incorporation of precursors | Measure de novo synthesis |
| Cell proliferation assay | Growth dependence on pathway | Evaluate drug sensitivity |
Metabolic Flux Analysis
Metabolic flux analysis using stable isotope tracers can quantify the activity of de novo pyrimidine biosynthesis in cells and tissues. This method reveals how pathway intermediates are channeled and how salvage contributes to nucleotide pools.
CRISPR Screening
Genome-wide CRISPR screens, such as uridine-sensitized screening, identify genes that regulate nucleotide synthesis, including NUDT5 and demethoxy-coenzyme Q. These screens link mitochondrial function and nucleotide metabolism.
Enzyme Activity Assays
In vitro enzyme assays measure the catalytic activity of individual pathway enzymes, such as DHODH and UMPS, using purified proteins or cell lysates. These assays are used to test inhibitors and characterize mutations.
Transcriptomics and Proteomics
RNA-seq and proteomics can assess expression changes in pathway genes under conditions of proliferation, stress, or drug treatment. In plants, these approaches reveal compartment-specific expression.
How CRISPR Can Be Used to Study GO:0006207 'de novo' pyrimidine nucleobase biosynthetic process
Knockout
CRISPR knockout of genes such as CAD or DHODH can abolish de novo pyrimidine synthesis, leading to auxotrophy for uridine and impaired proliferation. Knockout models are used to confirm essentiality and to study compensatory salvage.
Point Mutation
Point mutations introduced by CRISPR can mimic clinical variants or alter catalytic residues, allowing structure-function studies of pathway enzymes. For example, mutations in UMPS can model orotic aciduria.
Knock-in
Knock-in of tagged or reporter alleles enables visualization and tracking of pathway enzymes in live cells. This approach can reveal subcellular localization and dynamics.
Overexpression
CRISPR activation or cDNA overexpression can drive pathway flux, modeling the upregulation seen in cancer. Overexpression models help identify rate-limiting steps and drug targets.
How EDITGENE Supports 'de novo' pyrimidine nucleobase biosynthetic process Research
Researchers studying 'de novo' pyrimidine nucleobase biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for 'de novo' pyrimidine nucleobase biosynthetic process research.
Frequently Asked Questions About 'de novo' pyrimidine nucleobase biosynthetic process
What is GO:0006207?
GO:0006207 is the Gene Ontology term for the 'de novo' pyrimidine nucleobase biosynthetic process, which describes the chemical reactions that build pyrimidine nucleobases from simple precursors.
What genes are involved in de novo pyrimidine nucleobase biosynthesis?
Key genes include CAD, DHODH, UMPS, CTPS1, and in plants PYR1-PYR6 and NUP1, among others.
Why is de novo pyrimidine synthesis important for cancer?
Cancer cells upregulate this pathway to support rapid proliferation and DNA repair, making it a therapeutic target.
How is de novo pyrimidine synthesis different from salvage?
De novo synthesis builds pyrimidine rings from simple precursors, while salvage recycles preformed nucleobases.
Is de novo pyrimidine biosynthesis required for Toxoplasma virulence?
Yes, genetic studies show that the pathway is required for Toxoplasma gondii virulence in animal models.
What diseases are linked to defects in pyrimidine biosynthesis?
Defects in UMPS cause orotic aciduria, and pathway dysregulation is linked to cancer and infectious diseases.
How can CRISPR be used to study this pathway?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal dissection of each pathway gene.
What methods measure de novo pyrimidine synthesis?
Metabolic flux analysis, isotope tracing, enzyme assays, and CRISPR screens are commonly used.
Where does de novo pyrimidine synthesis occur in plant cells?
In Arabidopsis, it occurs mainly outside plastids, with a nucleobase importer supporting salvage.
What is the role of NUDT5 in nucleotide synthesis?
NUDT5 was identified as a regulator of nucleotide synthesis in uridine-sensitized CRISPR screens.
Conclusion
GO:0006207, the 'de novo' pyrimidine nucleobase biosynthetic process, is a fundamental metabolic pathway that supplies pyrimidine nucleobases for nucleic acid synthesis and cellular function. Its dysregulation is implicated in cancer, infectious diseases, and inherited metabolic disorders, making it a rich area for research and drug discovery. Advances in CRISPR modeling and metabolic screening continue to reveal new regulators and therapeutic opportunities.
References
- 1. Strefeler A et al.. 2025. Uridine-sensitized screening identifies demethoxy-coenzyme Q and NUDT5 as regulators of nucleotide synthesis.. Nat Metab 7(11):2221-2235 PMID: 41233602
- 3. Yi J et al.. 2022. A Nonenzymatic Analog of Pyrimidine Nucleobase Biosynthesis.. Angew Chem Int Ed Engl 61(23):e202117211 PMID: 35304939
- 4. Fox BA et al.. 2002. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii.. Nature 415(6874):926-9 PMID: 11859373
- 5. Witz S et al.. 2012. De novo pyrimidine nucleotide synthesis mainly occurs outside of plastids, but a previously undiscovered nucleobase importer provides substrates for the essential salvage pathway in Arabidopsis.. Plant Cell 24(4):1549-59 PMID: 22474184
- 6. Joshi R et al.. 2026. De novo or Salvage? Nucleotide Availability as a Driver of Bacterial Adaptation and Virulence.. Microbiologyopen 15(4):e70358 PMID: 42393866
- 7. Lin JC et al.. 2024. Connecting dots between nucleotide biosynthesis and DNA lesion repair/bypass in cancer.. Biosci Rep 44(9) PMID: 39189649
- 8. Zrenner R et al.. 2006. Pyrimidine and purine biosynthesis and degradation in plants.. Annu Rev Plant Biol 57:805-36 PMID: 16669783
